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http://dx.doi.org/10.1016/j.ccell.2015.04.007SUMMARYMyelodysplastic syndrome (MDS) risk correlates with advancing age, therapy-induced DNA damage, and/or
shorter telomeres, but whether telomere erosion directly induces MDS is unknown. Here, we provide the ge-
netic evidence that telomere dysfunction-induced DNA damage drives classical MDS phenotypes and alters
common myeloid progenitor (CMP) differentiation by repressing the expression of mRNA splicing/process-
ing genes, including SRSF2. RNA-seq analyses of telomere dysfunctional CMP identified aberrantly spliced
transcripts linked to pathways relevant to MDS pathogenesis such as genome stability, DNA repair, chro-
matin remodeling, and histone modification, which are also enriched in mouse CMP haploinsufficient for
SRSF2 and in CD34+ CMML patient cells harboring SRSF2mutation. Together, our studies establish an inti-
mate link across telomere biology, aberrant RNA splicing, and myeloid progenitor differentiation.INTRODUCTION
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and oxidative defense (Jaskelioff et al., 2011). Model systems
have established that these DNA damage corollaries contribute
to tissue degenerative phenotypes (Sahin and DePinho, 2012).f hematopoietic neoplastic disorders. While MDS risk corre-
/or shorter telomeres, whether DNA damage signaling can
lomerase reverse transcriptase-estrogen receptor (TERTER)
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A source of age-associated DNA damage signaling can derive
from progressive telomere erosion and damage which appears
to provide a reservoir of persistent DNA damage signaling in
the context of aging cells (Chin et al., 1999; d’Adda di Fagagna
et al., 2003; Karlseder et al., 2002; Rudolph et al., 1999). These
processes are particularly evident in tissues with high cell turn-
over rate, including the hematopoietic system (Lee et al., 1998;
Rudolph et al., 1999). Indeed, accumulating evidence supports
the view that DNA damage checkpoints activated by telomere
erosion can drive hematopoietic stem cell (HSC) decline, thereby
compromising HSC self-renewal, repopulating capacity, and dif-
ferentiation (Rossi et al., 2007; Wang et al., 2012). While acute
DNA damage can trigger a p53-mediated apoptosis or senes-
cence of hematopoietic progenitor cells (Insinga et al., 2013;
Milyavsky et al., 2010), whether and how accumulating physio-
logical or pathological DNA damage (including telomeres) might
influence the differentiation decisions of hematopoietic progen-
itor cells has not been explored. Of relevance to this study, it is
worth noting that the specific type of cellular response (e.g.,
apoptosis, cell cycle, etc.) in telomere dysfunctional mice can
vary depending on cell type (Lee et al., 1998).
Myelodysplastic syndrome (MDS) is a very heterogeneous
group of hematopoietic disorders characterized by ineffective
myeloid differentiation, dysplasia, and excessive DNA damage
accumulation in stem/progenitor cells (Zhou et al., 2013). MDS
incidence has risen dramatically in recent years (Rollison et al.,
2008) and is associated with advanced age, shorter telomeres,
cancer chemotherapy with alkylating agents, radiation, and in-
herited syndromes related to abnormalities in DNA repair
(Zhou et al., 2013). On the genomic level, MDS alterations
include chromosomal abnormalities (loss of 5q, 7 or 7q, 20q,
and/or Y, and trisomy 8), point mutations of NRAS or KRAS
and/or TP53 as well as genes involved in DNA methylation
(DNMT3A, TET2, IDH1, and IDH2), chromatin remodeling
(ASXL1 and EZH2), splicing regulation (SF3B1, SRSF2,
U2AF1, U2AF2, SF3A1, ZRSR2, SF1, and PRPF40B) (Bejar
et al., 2011; Larsson et al., 2013), and telomerase complex
(TERT, RTEL1, and TINF2). While the HSCs harboring these
mutations are the cell-of-origin for MDS (Will et al., 2012)
and are responsible for clonal dominance, derivative com-
mitted progenitors from these HSCs manifest skewed dif-
ferentiation resulting in the morphological and clinical pheno-
type of MDS. Herein, we sought to understand if telomere
dysfunction and persistent DNA damage signaling activation
can be the primary instigators of MDS in the absence of
MDS-associated gene mutations or genetic alterations, and
how hematopoietic progenitor cells can contribute to ineffec-
tive differentiation that maintains MDS and eventually results
in disease progression.
RESULTS
Telomere Dysfunctional Mice Exhibit Hallmarks of
Human MDS
Recognizing that the biological response to telomere dysfunc-
tion is highly cell type dependent (Lee et al., 1998), we sought
to catalog the cell biological and molecular responses to telo-
mere dysfunction in various hematopoietic lineages and assess
their potential role inMDS pathogenesis. Tomodel chronic phys-iological DNA damage in the hematopoietic system, we em-
ployed the inducible telomerase model, TERTER, engineered to
encode a telomerase reverse transcriptase-estrogen receptor
fusion protein that can be activated by 4-hydroxytamoxifen
(OHT) treatment. Inter-generational crosses of TERTER/ER mice
leads to progressive telomere erosion, which by the fourth and
fifth generations (G4/G5) elicits telomere dysfunction and asso-
ciated DNA damage signaling and severe tissue degeneration
(Jaskelioff et al., 2011). In the late generation G4/G5 TERTER/ER
mice, systemic administration of OHT restores telomeres, quells
DNA damage signaling, and reverses tissue degeneration phe-
notypes (Jaskelioff et al., 2011).
We first audited in-depth the phenotypic impact of telomere
dysfunction on the hematopoietic system in 3-month- and 7-
month-old G4/G5 TERTER/ER mice. These analyses revealed
significant cytopenias in the peripheral blood, a decline in lym-
phopoiesis, slight anemia, and moderate granulo-monocytosis
in advancing age (Figure 1A). Bone marrow (BM) hyper-cellu-
larity and increased myeloid-to-erythroid progenitor (M:E) ratio
(Figure 1B), in the absence of increased apoptosis (Fig-
ure S1A), were consistent with a condition of myeloid-skewed
differentiation and ineffective hematopoiesis. Further BM
analysis revealed severe tri-lineage dysplasia (Figure 1C:
hypersegmented neutrophils [29% ± 7.39%], erythroblasts
[18.25% ± 7.13], and megakaryocytes [44.75% ± 20.27%]),
absence of ring sideroblasts (Figure S1B), and increase of
immature, morphologically abnormal myeloid blasts (Figure 1D,
top: % of blasts: 10%–15% and myeloperoxidase positive
blasts: 78% ± 10.81%) frequently with pronounced monocytic
differentiation (Figure 1D, bottom: butyrate esterase positive
blasts: 35.75% ± 3.30%), which recapitulated the hallmark
features of refractory anemia with excess of blasts (RAEB)
in 80% of cases or chronic myelo-monocytic leukemia
(CMML) in 20% of cases, specific sub-groups of MDS that
are characterized by a high propensity to develop acute
myeloid leukemia (AML). Accordingly, approximately 5% of
aged G4/G5 TERTER/ER mice progressed to AML, as demon-
strated by a marked increase of BM myeloid blasts (more
than 20% of BM cellularity) (Figure 1E) and infiltration of
myeloid precursors into the splenic white-red pulp architec-
ture, resulting in myeloid sarcoma with the complete efface-
ment of lymphoid follicles (Figure 1F). Cytogenetic analysis
of G4/G5 TERTER/ER BM cells showed chromosomal breaks
and fusions (Figure S1C), which eventually fuel chromosomal
translocations (Figure S1D).
Telomerase Reactivation Rescues Impaired Progenitor
Cell Differentiation in Telomere Dysfunctional Mice
To study the cellular mechanisms underlying skewed myeloid
differentiation induced by telomere attrition and given the impor-
tant contribution of the hematopoietic progenitor compartment
toward ineffective hematopoiesis and MDS phenotype, we
examined the c-Kit+ScaLin (KSL) compartment that repre-
sents a key branch at which HSC-derived progenitors commit
to various myeloid lineages (Akashi et al., 2000) (Figure S2A).
Compared to age- and gender-matched G0 TERTER/+ controls,
the KSL compartment of G4/G5 TERTER/ER mice showed a
significant increase in the frequency (Figure 2A) and absolute
number (Figure S2B) of granulocyte-macrophage progenitorsCancer Cell 27, 644–657, May 11, 2015 ª2015 Elsevier Inc. 645
Figure 1. The Hematopoietic Compartment of Telomere Dysfunctional Mice Recapitulates Hallmark Features of Human MDS
(A) Complete blood count evaluation of age-matched young (3-month-old) and old (7-month-old) mice of indicated genotypes (top panel) (error bars denote SEM).
Relative abundance of neutrophils and lymphocytes in total white blood cells of young and old mice of indicated genotypes (bottom panel) (error bars denote SEM).
(B) Hematoxylin and eosin (H&E) stained sections of BM biopsies of representative G0 (left panel) and G5 (right panel) mice. The scale bar represents 50 mi-
crometers (mm).
(C) Pattern of multi-lineage differentiation in a representative G0 BM cytospin (left panel); dysplastic neutrophil (N), erythroblast (E), and megakaryocyte (M) in a
representative G5 BM cytospin (central and right panels). The scale bar represents 15 mm.
(D) Myeloperoxidase (MPO) (top panel) and butyrate esterase (bottom panel) cytochemical staining of a representative G0 (on the left) or G5 (on the right) BM
cytospin. Arrows indicate positive blasts. The scale bar represents 15 mm.
(E) Pattern of multi-lineage differentiation in a representative G0 BM cytospin (left panel); increased number of BM blasts (>20% of BM cellularity) in the BM
cytospin of a representative G5 mouse in transformation (right panel). The scale bar represents 15 mm.
(F) H&E stained splenic section of a representative G0 mouse (top, left panel) or G5 mouse in transformation (top, right panel). The scale bar represents 200 mm.
Myeloid cells infiltrating the white-red pulp are positive for CD11b (bottom, left panel) and MPO (bottom, right panel). The scale bar represents 15 mm. See also
Figure S1.
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Figure 2. Skewed Myeloid-Erythroid Differentiation of CMP Is Reversed by Telomerase Reactivation
(A) KSL frequency in the BM, as well as the CMP, GMP, and MEP frequencies in the KSL population of indicated genotypes and treatments (mean and SEM of
age-matched 3-month-old mice from six independent experiments of telomerase reactivation in vivo; data are expressed as percentage of corresponding
controls).
(B) Anti-gH2AX immunofluorescence in CMP sorted from mice of indicated genotypes and treatments: numbers of gH2AX foci per cell (upper panel; error bars
denote SD) and representative images (bottom panel): a-gH2AX: green and DAPI: blue. The scale bar represents 20 mm.
(C and E) Frequency of the erythroid lineage in the BM (C, left) and spleen (E, upper) of indicated genotypes and treatments (mean and SEM of mice from two
independent experiments of telomerase reactivation in vivo; data are expressed as percentage of corresponding controls), representative Ter119-stained
sections of BM (C, right; scale bar represents 100 mm) and spleen (E, bottom) from age-matched controls and experimental mice (the scale represents 200 mm).
(D) H&E stained BM section of a representative G5 mouse without (left panel) or with OHT treatment (right panel; the scale bar represents 15 mm). See also
Figure S2.(GMP; KSL CD34+FcgRhi), with the concomitant loss of mega-
karyocyte-erythroid progenitors (MEP; KSL CD34FcgR/lo)
and slight reduction of common myeloid progenitors (CMP;KSL CD34+FcgR/lo), in the absence of increased apoptosis
in these populations (data not shown). These observations gain
added significance in light of recent findings that a significantCancer Cell 27, 644–657, May 11, 2015 ª2015 Elsevier Inc. 647
expansion of theGMP compartment occurs in the RAEB stage of
MDS patients with higher risk of leukemic transformation (Pang
et al., 2013; Will et al., 2012). Notably, the GMP population
further increased in the agedG4/G5 TERTER/ERmice (Figure S2C)
or during leukemic transformation (data not shown). Further
analysis of the hematopoietic sub-populations showed a prefer-
ential accumulation of g-H2AX and 53BP1 DNA damage foci in
the telomere dysfunctional CMP (Figures 2B and S2D), but not
in GMP or MEP (Figures S2E and S2F), suggesting that various
sub-types of hematopoietic progenitors may respond differently
to telomere erosion.
To determine whether elevated telomere associated DNA
damage was the instigator for skewed myeloid-erythroid differ-
entiation, we reactivated telomerase in 3-month-old telomere
dysfunctional mice to restore telomere function and thus quell
DNA damage signaling. Following 40 days of continuous OHT
exposure, total BM cells showed increased telomere length as
measured by flow-fluorescence in situ hybridization (FISH) and
a significant reduction of signal-free ends (Figures S2G and
S2H). Telomere restoration was associated with a significant in-
crease inMEP frequency (Figure 2A), MEP absolute number (Fig-
ure S2B), and a corresponding reduction of GMP. Furthermore,
characterization of the progenitor compartment in the early
generation telomerase deficient mice (G1) without telomere
dysfunction showed no aberrant myeloid differentiation (Fig-
ure S2I), suggesting that skewed myeloid differentiation in
G4/G5 mice is attributed to DNA damage activation, and not
the absence of telomerase per se. Together, these data support
the view that telomere attrition-induced DNA damage itself can
serve as a driver of altered myeloid progenitor differentiation, re-
sulting in a persistent accumulation of the myeloid lineage at the
expense of the MEP population, a process fundamental to MDS
pathogenesis.
Telomerase reactivation was also associated with signifi-
cantly reduced g-H2AX and 53BP1 foci of the CMP population
(Figures 2B and S2D). The recovery of the MEP population
upon sustained OHT treatment tracked with a significant resto-
ration of BM Ter119+ erythroid progenitors (Figure 2C) in all
developmental stages (data not shown), an improvement of
M:E ratio and reduction of immature myeloid cells in the BM
(Figure 2D) and decline of splenic extra-medullary erythropoi-
esis (Figure 2E). Thus, endogenous telomerase reactivation
and extinction of DNA damage signaling restores the normal
myeloid differentiation process, reinforcing the link between
telomere dysfunction and aberrant myeloid differentiation.
Nevertheless, the failure of telomerase reactivation to rescue
the KSL decline (Figure 2A) implicates the existence of addi-
tional upstream differentiation checkpoints involving the stem
cell compartment as previously reported (Rossi et al., 2007;
Wang et al., 2012). Consistent with the expansion of phenotyp-
ically primitive HSCs occurring in MDS (Will et al., 2012), the
telomere dysfunctional HSC compartment (KSL) showed an
increased expansion in the steady-state frequency of long-
term HSC (LT-HSC; c-Kit+Sca+LinCD34flk2) and short-
term HSC (ST-HSC; c-Kit+Sca+LinCD34+flk2), with the
concomitant decrease of multi-potent progenitor cells (MPP;
c-Kit+Sca+LinCD34+flk2+) (Figures S2J and S2K), and
compromised repopulation capability upon BM competitive
transplantation (Figure S2L).648 Cancer Cell 27, 644–657, May 11, 2015 ª2015 Elsevier Inc.Defective CMP Differentiation Is due to Cell Intrinsic
DNA Damage Signaling Activation
Impaired progenitor differentiation could occur as a result of a
telomere dysfunctional systemic environment that limits HSC
function and organ homeostasis (Ju et al., 2007) and/or cell
intrinsic defects of telomere dysfunctional hematopoietic cells
(Allsopp et al., 2003). To distinguish between the two possibil-
ities, we transplanted LT-HSC isolated from 3-month-old G0 or
G4/G5 mice into wild-type congenic recipients and assayed
recipient BM for donor-derived progenitor cell frequencies
2 months post-transplantation. Analysis of the G4/G5 derived
hematopoietic system revealed that the level of donor-derived
skewedmyeloid differentiationwas comparable to that observed
at steady state in the same young telomere dysfunctional mice
before transplantation (Figure 3A). Furthermore, G4/G5 trans-
planted BM showed severe tri-lineage dysplasia and an increase
of immature, morphologically abnormal myeloid blasts. Notably,
one of the six mice transplanted with G5 HSC progressed to
AML, as demonstrated by a marked increase of BM myeloid
blasts and infiltration of myeloid precursors into the splenic
white-red pulp architecture (Figure 3B). Overall, these findings
demonstrate that telomere dysfunction exerts a prominent cell-
intrinsic effect on the differentiation commitment of progenitor
cells and are consistent with the existence of ‘‘diseased’’ stem
cells that are capable of regenerating the MDS phenotype after
transplantation in wild-type mice.
Additionally, in the light of recent findings showing that
megakaryocyte and MEP can also directly differentiate from
HSC (Yamamoto et al., 2013), we evaluated if the CMP is
responsible for the skewed myeloid differentiation of telomere
dysfunctional mice as suggested from the in vivo experiments.
To this end, we sorted G0 and G4/G5 CMP and determined
their differentiation potential in methylcellulose clonogenic
assay. Consistent with the in vivo results (Figure 2A), there
was a profound impairment of myeloid differentiation toward
the erythroid lineage in favor of granulo-monocytic commit-
ment in the telomere dysfunctional CMP which was partially
rescued upon telomerase reactivation (Figure 3C; data not
shown). Similar results were obtained in clonogenic assays
of BM mononuclear cells (MNCs) (Figure S3A), as well as
HSCs upon long-term culture (LTC-IC) (data not shown). On
the basis of these in vivo and in vitro data, we conclude
that telomere dysfunction affects myeloid differentiation.
Next, we explored the nature of DNA damage signaling and
its impact on CMP differentiation processes. We observed
that a highly specific inhibitor of the ataxia telangiectasia
and Rad3 related (ATR), but not ataxia telangiectasia mutated
(ATM) kinase, partially improved erythroid differentiation of
telomere dysfunctional CMP (Figure 3D), a finding consistent
with a known role for ATR in telomere dysfunction and ag-
ing-induced replicative stress signaling (Kastan and Bartek,
2004) (p = 2.2 3 1010; Figure S3B). Correspondingly, our
clinical correlative studies showed that ATR phosphorylation
(p-ATR) status in the CD34+ cells correlates with high risk
MDS, which is characterized by an expanded GMP population
at the expense of MEP (Pang et al., 2013; Will et al., 2012). We
observed p-ATR signal in only five of 25 patients samples
exhibiting low risk MDS versus 23 of 32 with high risk MDS
(p = 0.00014) (Figure S3C). Collectively, these data indicate
Figure 3. Defective CMP Differentiation Is due to Cell Intrinsic DNA Damage Signaling Activation
(A) CMP, GMP, andMEP frequencies in the KSL population of G0 or G5mice before and after HSC transplantation in wild-type recipient mice (error bars denote
SEM; data are expressed as percentage of corresponding controls).
(B) Representative BM cytospin of one recipient mouse transplanted with G5 HSCs (on the left). Arrows indicate blastic cells. Massive infiltration of CD11b
positive myeloid precursors into the splenic white-red pulp architecture of a recipient mouse transplanted with G5 HSCs (on the right) (the scale bar represents
100 mm).
(C) Clonogenic myeloid colony formation in methylcellulose from sorted CMP of indicated genotypes cultured in the presence of vehicle or OHT. Erythroid cells
were scored by benzidine staining and expressed as frequency of the total number of colonies (mean and SEM of replicates from six experiments of telomerase
reactivation in vitro; each experiment includes equal number of CMP sorted from independent mice of indicated genotypes; and data are expressed as per-
centage of G0 control).
(D) Clonogenic myeloid colony formation in methylcellulose from sorted CMP of indicated genotypes pre-treated with vehicle, ATR inhibitor (ATR-I, 1 micromolar
[mM]), or ATM inhibitor (ATM-I, 2 mM) for 1 hr. Erythroid cells were scored by benzidine staining and expressed as frequency of the total number of colonies (mean
and SEM of replicates from three independent experiments, each experiment includes equal number of CMP sorted from independent mice, and data are
expressed as percentage of G0 control).
(E) Clonogenic myeloid colony formation in methylcellulose from sorted wild-type CMP isolated from control or IR (3 Gy) mice (left panel) or pre-treated with
vehicle or cisplatin (5 mM) for 4 hr (right panel). Erythroid cells were scored by benzidine staining and expressed as frequency of the total number of colonies (mean
and SEM of replicates from three and two independent experiments, respectively; each experiment includes CMP sorted from a pool of three wild-typemice; and
data are expressed as percentage of corresponding controls).
(F) Clonogenic myeloid colony formation in methylcellulose from sorted CMP isolated from 9-month-old wild-typemice 4months after sub-lethal IR. Control mice
indicate age-matched wild-type mice without IR. Erythroid cells were scored by benzidine staining and expressed as frequency of the total number of colonies
(mean and SEM of replicates from four or five mice for each condition; equal number of CMP was sorted from independent mice; and data are expressed as
percentage of control). See also Figure S3.the existence of a cell intrinsic telomere dysfunction-induced
differentiation checkpoint, which occurs at the level of progen-
itor cells and contributes to ineffective hematopoiesis, a key
feature of the MDS phenotype.
Next, we sought additional evidence to cement the role of DNA
damage in alteringmyeloid differentiation. Employing ionizing ra-
diation and cisplatin treatment as distinct instigators of DNA
damage signaling, sorted CMP from wild-type mice subjectedto irradiation (IR, 3 Gy) or cisplatin treatment (5 mM, 4 hr of
cisplatin treatment) show impaired erythroid differentiation
(Figure 3E). Notably, skewed myelo-erythroid differentiation
occurred even 4 months after sub-lethal IR of wild-type mice
(Figure 3F), consistent with recent findings showing that brief
exposure to a moderate level of DNA damage is sufficient to
maintain chronic DNA damage signaling activation in hemato-
poietic cells (Insinga et al., 2013).Cancer Cell 27, 644–657, May 11, 2015 ª2015 Elsevier Inc. 649
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Figure 4. Telomere Dysfunction Induces Aberrant RNA Splicing by Repressing Splicing Gene Expression in CMP
(A) Significantly downregulated and upregulated pathways identified by GSEA in G4/G5 compared to G0 CMP (false discovery rate = 0.05).
(B) Fluidigm-based gene expression analysis of single cells (rows) for representative genes in themRNAprocessing/spliceosome pathways (columns) fromGSEA,
which are significantly altered in sorted CMP from the G0 and G5 mice with or without OHT treatment (n = 3). The genes analyzed were (from left to right): ACTB,
b2M, GAPDH (housekeeping genes; internal controls), U2AF2, SF3B2, SF3A3, SRSF2, SFPQ, SFRS10, SFRS2IP, CDC51, DDX46,WBP11, SMC1A, PAPOLA,
SRRM1, FUS, RBM5, and NUP54. A full gene list is shown in Table S2. The color scale on the right shows correspondence between color code and Ct values.
(legend continued on next page)
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TelomereDysfunction InducesAberrant RNASplicing by
Repressing Splicing Gene Expression in CMP
Next, to determine the mechanistic bases of how telomere
dysfunction-induced DNA damage may drive abnormal myeloid
differentiation, we performed gene expression profiling analysis
of sorted CMPcells from age- and gender-matchedG0 or G4/G5
TERTER/ER mice. Gene set enrichment analysis (GSEA) of the
differentially expressed genes of the G4/G5 TERTER/ER CMP re-
vealed a significant enrichment of genes involved in mRNA
splicing and processing (Figure 4A; Table S1), including the
splicing factors U2AF2, SRSF2, SRSF10, SF3B2, and SF3A3.
To exclude the possibility that the changes in splicing gene
expression were due to cellular heterogeneity in the CMP, we
performed single cell Fluidigm real-time PCR and observed a
consistent repression of splicing gene expression in every G4/
G5 CMP compared to the G0 control (Figure 4B; Table S2), indi-
cating that telomere dysfunction leads to a homogeneous
change in splicing gene expression during this particular stage
of differentiation. That the splicing pathway was downregulated
in the G4/G5 CMPwas further validated by western blot analysis
(Figure S4A). In striking contrast, the RNA splicing pathway
was not altered in the G4/G5 TERTER/ER GMP (Figure S4B) or
MEP (data not shown), a finding which aligns with a lack of a
significant g-H2AX and 53BP1 DNA damage foci increase in
these sub-populations (Figures S2E and S2F) and underscores
the context-specific impact of DNA damage signaling in
the differentiating hematopoietic system. Interestingly, the
CMP population also showed preferential and significant down-
regulation of genes belonging to the cohesin complex (RAD21,
STAG1, SMC2, and SMC5) (Table S1) that is known to be
involved in post-replicative DNA repair (Dorsett and Stro¨m,
2012), and recurrently mutated or deleted in AML and MDS
(Kon et al., 2013; Ley et al., 2013), suggesting that DNA damage
accumulation in the CMP cells could be further potentiated
by the impairment of pathways regulating the DNA damage
repair.
Weobservedanoverrepresentationof splicinggenesbelonging
to the same interaction network (Figure 4C), which is known to be
involved in the 30splice site recognition and toplay a critical role for
commitment complex E formation in U2-dependent splicing or for
stabilization of splicing complex A. Remarkably, highly recurrent
mutations in some of these same key components of the spliceo-
somemachinery and their interacting partners have been recently
reported in MDS (Yoshida et al., 2011), although little is known
about how these mutations contribute to the pathogenesis of
MDS or its transformation to AML.
To fortify the link between telomere dysfunction-induced
DNA damage and suppressed expression of the mRNA
splicing and processing components, we quantified the
mRNA expression of these genes upon telomerase reactiva-
tion and observed that the downregulation of mRNA splicing(C) Interaction network of splicing genes significantly downregulated inG4/G5CM
of a given protein with other splicing components. * indicates splicing factors mu
(D) Fluidigm-based gene expression analysis of single cells (rows) for representati
significantly altered in sorted CMP from the G0 and G5mice with or without ATR in
(from left to right): ACTB, b2M, GAPDH (housekeeping genes; internal controls)
PAPOLA, SRRM1, and RBM5. The color scale on the right shows corresponden
(E) Significantly enriched pathways relative to the 1,940 aberrantly spliced genesand processing components, which was absent in G1 mice
(data not shown), was rescued by telomerase reactivation in
the G4/G5 mice (Figure 4B). The repression of mRNA splicing
and processing components persisted in CMP after the trans-
plantation of telomere dysfunctional HSC in wild-type recipient
mice (Figure S4C), establishing that telomere dysfunction-
induced DNA damage exerts a prominent cell-intrinsic effect
on mRNA splicing regulation. Furthermore, splicing repression
in the CMP was significantly rescued when telomere dysfunc-
tional mice were treated with the specific ATR kinase inhibitor
VE-821 (Figure 4D), a finding in accord with decreased p-ATR
immunofluorescence staining of the CMP after VE-821 treat-
ment (Figure S4D).
Together, these findings indicate that the cell intrinsic telomere
dysfunction-induced DNA damage response can impact on the
expression of genes involved in splicing regulation through the
activation of ATR kinase. In correlative clinical studies, the link
between splicing factor expression levels and ATR activation
is further supported by a significant correlation between
decreased srsf2 levels and the phosphorylation status of ATR
in MDS CD34+ cells (n = 50, p = 0.04, data not shown).
Given that telomere dysfunction results in the downregula-
tion of splicing components, we performed RNA sequencing
(RNA-seq) analysis on G0 and G4/G5 TERTER/ER CMP to
assess if the RNA splicing process is indeed altered. Notably,
this analysis detected a total of 2,489 aberrant splicing events
affecting 1,940 genes in the G4/G5 TERTER/ER CMP compared
to G0 control (Table S3), among which 40.5% and 59.5% of
aberrant splicing events would result in exon skipping and
exon retention, respectively, consistent with the decreased
expression of factors that define the exon-intron boundaries
(Figure 4C). Furthermore, we found that 26.9% of aberrant
splicing events are predicted to produce loss-of-function tran-
scripts that arise mainly due to a premature stop codon (Table
S4) or an in-frame deletion disrupting known functional do-
mains (Table S5). There were no changes in intron retention
(data not shown), which we speculate may result from
increased expression of genes involved in the nonsense-medi-
ated mRNA decay response present in G4/G5 TERTER/ER CMP
(Zhang and Manley, 2013) (Figure 4A). Of note, the aberrantly
spliced transcripts in the G5 CMP population are enriched in
pathways that are highly relevant to the MDS phenotype,
including the maintenance of genome stability, DNA damage
response, chromatin remodeling, and histone modifications
(such as acetylation, methylation, sumoylation, and ubiquitina-
tion) (Figure 4E).
Epigenetic alterations and histone code changes drive aber-
rant differentiation of MDS cells, which are sensitive to drugs
that modify the epigenome and influence DNA methylation
(Issa, 2013). In this regard, it is notable that, among the aberrantly
spliced epigenetic regulators in G5 CMP, the protein level ofP (blue color). The size of the nodes is proportional to the number of interactions
tated in MDS.
ve genes in the mRNA processing/spliceosome pathways (columns), which are
hibitor treatment (n = 2 or 3 mice for each condition). The genes analyzed were
, U2AF2, SF3B2, SF3A3, SRSF2, SFPQ, SFRS10, SFRS2IP, CDC51, DDX46,
ce between color code and Ct values.
(p < 0.05). See also Figure S4 and Tables S1, S2, S3, S4, and S5.
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DNMT3A DNA methyltransferase decreased due to premature
termination of protein translation (Figure S4A) as a result of a
frameshift that occurs upon exon skipping (Table S4). In MDS
patients, recurrent mutations in DNMT3A reduce the methyl-
transferase activity of the protein and are associated with rapid
progression to AML (Walter et al., 2011). Supporting the view
that the loss of DNMT3A may impact on DNA methylation, we
found locus-specific changes in methylation patterns in the G5
CMP compared to G0 control, involving both gains and losses
of methylation in CpG promoters, gene bodies, and intergenic
regions (Figures S4E and S4F). These findings are consistent
with previous studies showing that DNMT3A loss in the hemato-
poietic system results in hypo- and hyper-methylation at distinct
loci, progressive impairment of differentiation (Challen et al.,
2012), and hematological malignancies including MDS (Mayle
et al., 2014).
SRSF2 Haploinsufficiency Impairs CMP Differentiation
in Mice
Recognizing that an optimal stoichiometry of splicing com-
ponents is critical for proper spliceosomal function (Ca´ceres
et al., 1994) and that either overexpressing or downregulating
particular splicing factors alters splicing activity, we sought
multi-level evidence of a causal link between decreased splicing
factor activity/expression and abnormal myeloid progenitor dif-
ferentiation. To that end, we evaluated whether pharmacological
or genetic perturbation of the splicing machinery could induce
defective myeloid differentiation similar to that observed in the
telomere dysfunctional CMP. Using Pladienolide B (PLA-B, a
natural macrolide that inhibits the spliceosome assembly
through specific Sf3b complex binding, see Kotake et al.,
2007), we observed that a transient (4 hr) pre-treatment of sorted
wild-type CMP cells prior to differentiation resulted in a profound
impairment of differentiation toward the erythroid lineage
(Figure S5A). Similar results were obtained with transient
NSC663284 treatment that inhibits the catalytic activity of the
splicing machinery (Berg et al., 2012) (Figure S5A).
To provide genetic evidence that decreased expression of
splicing components impacts progenitor differentiation toward
the erythroid lineage, we generated mice heterozygous
for SRSF2 by crossing conditional SRSF2 knockout mice
(SRSF2L/L) with hematopoietic cell-specific cre transgenic mice
(Vav-cre). SRSF2 is a well-characterized splicing factor involved
in both constitutive and regulated splicing (Lin and Fu, 2007) and
is significantly downregulated in telomere dysfunctional CMP
and recurrently mutated in MDS patients (Yoshida et al., 2011).
Although the Vav-cre/ SRSF2L/+ mice showed no obvious hema-
topoiesis defect in the peripheral blood (data not shown),
analysis of the Vav-cre/ SRSF2L/+ BM revealed multi-lineage
dysplasia (Figure 5A: hypersegmented neutrophils [20.5% ±
7.76%], erythroblasts [14.75% ± 2.06], and megakaryocytes
[27.25% ± 10.93%]), a slight increase in the number of morpho-
logical abnormal blasts (Figure 5A: 13% ± 7.57%), and myelo-
monocytosis (Figure 5B: % of butyrate esterase positive cells
is 7% ± 2% in the Vav-cre BM versus 16.33% ± 4.67% in the
Vav-cre/SRSF2L/+ BM, p = 0.003 and % of CD11b positive cells
is 41.66% ± 2.88% in the Vav-cre BM versus 67.5% ± 9.57% in
the Vav-cre/SRSF2L/+ BM, p = 0.008). Compared to the age- and
gender-matched Vav-cre controls, the KSL compartment of the652 Cancer Cell 27, 644–657, May 11, 2015 ª2015 Elsevier Inc.Vav-cre/SRSF2L/+ mice showed a slight increase in the fre-
quency of GMP with the concomitant loss of MEP (Figure 5C),
which was further confirmed by in vitro methylcellulose clono-
genic assay of sorted CMP (Figure 5D).
Aberrant RNA Splicing due to Reduced SRSF2
Expression Induces Telomere Dysfunction
Next, RNA-seq analysis of Vav-cre and Vav-cre/ SRSF2L/+ CMP
confirmed altered RNA splicing associated with SRSF2 haploin-
sufficiency, detecting 1,682 aberrant splicing events for 1,357
genes (Table S6). Strikingly, these aberrantly spliced genes are
involved in telomere maintenance, chromatin remodeling, and
DNA repair pathways and show overlap to those genes altered
in the telomere dysfunctional CMP (Figure 6A). Consistent with
the aberrant splicing and predicted loss-of-function of telomere
maintenance genes including RTEL1 and TERF2IP (Figure S6A),
SRSF2 deletion was associated with a significantly increased
number of telomere dysfunction-induced foci in the CMP popu-
lation (Figure 6B) and decreased telomere length in BMcells (Fig-
ure 6C). Together, the concordance of RNA splicing profiles of
SRSF2 haploinsufficient and telomerase deficient CMP strongly
reinforce the intimate connection between RNA splicing, telo-
mere biology, DNA repair, and MDS phenotype.
Finally, we asked if this functional link was indeed relevant to
the human counterpart of MDS, which harbors somatic muta-
tions of spliceosomal genes in over half of all patients (Yoshida
et al., 2011). Since CMML patients are also characterized by
skewed myeloid differentiation toward the myelo-monocytic
lineage and present high rate of SRSF2 mutation (hence poten-
tially affecting RNA splicing) (Itzykson et al., 2013), we evaluated
SRSF2mutation (P95)-specific exon usage patterns by RNA-seq
analysis of SRSF2 mutant (n = 6) and wild-type (n = 9) CD34+
cells isolated from CMML patients, to understand the functional
consequences of SRSF2 mutation on RNA processing/splicing.
This analysis detected a total of 1,536 aberrant splicing events
affecting 1,355 genes (Table S7), mainly involved in DNA repair
and telomere maintenance pathways (Figure 6D), which overlap-
ped with the telomere dysfunctional (Figure 4E) and SRSF2 hap-
loinsufficient CMP RNA-seq data sets (Figure 6A). Specifically,
we found that transcripts encoding ACD, which is a component
of the shelterin telomeric complex, and TNKS, which interacts
with TRF1, to be aberrantly spliced in CD34+ cells with SRSF2
mutation, with predicted loss of function of these telomere main-
tenance genes. Together, these findings strongly support the
view that perturbation of RNA splicing either through loss of
SRSF2 expression or SRSF2 mutation results in the aberrant
splicing of a specific subset of genes, including those that influ-
ence telomere dynamics, which is predicted to induce telomere
dysfunction and exacerbate aberrant RNA splicing.
DISCUSSION
Our study provides multi-level evidence that telomere dysfunc-
tion can be a critical factor driving MDS and that diminished
splicing factor expression induced by telomere dysfunction
drives myeloid differentiation processes in a manner that con-
tributes to the high risk MDS phenotype. On the mechanistic
level, genetic, pharmacological, and correlative clinical data
establish that telomere dysfunction represses the expression
Figure 5. SRSF2 Haploinsufficiency Induces Skewed Myeloid Differentiation of CMP
(A) Dysplastic monolobated and hyperlobated (upper panel, on the left) or multi-nucleated (upper panel, on the right) megakaryocytes (M), dysplastic erythroblast
(E, bottom left) and abnormal (bottom panel, in the middle), and mitotic (bottom panel, on the right) blasts (B) in a representative Vav-cre/ SRSF2L/+ BM cytospin
(the scale bar represents 15 mm).
(B) Butyrate esterase cytochemical staining of a representative Vav-cre (upper panel, on the left) or Vav-cre/ SRSF2L/+ BM cytospin (upper panel, on the right).
CD11b stained sections of BM biopsies of representative Vav-cre (bottom panel on the left) and Vav-cre/ SRSF2L/+ (bottom panel on the right) mice (the scale bar
represents 15 mm).
(C) KSL frequency in the BM, as well as the CMP, GMP, and MEP frequencies in the KSL compartment of 2-month-old Vav-cre (n = 5) or Vav-cre/ SRSF2L/+
(n = 5) mice (error bars denote SEM; data are expressed as percentage of the Vav-cre control).
(D) Clonogenic myeloid colony formation in methylcellulose from CMP sorted from Vav-cre or Vav-cre/ SRSF2L/+ mice. Erythroid cells were scored by benzidine
staining and expressed as frequency of the total number of colonies (mean and SEM of replicates from five independent mice; data are expressed as percentage
of Vav-cre control). See also Figure S5.of genes governing RNA splicing in part through ATR. Notably,
on the clinical level, increased p-ATR staining is strongly corre-
lated with high risk MDS in patients, a finding of therapeutic clin-
ical utility in the prevention and treatment of aging-associated or
therapy-induced MDS.
An unexpected finding from our study is the highly specific
impact of telomere dysfunction and DNA damage on progenitor
differentiation and RNA splicing. We propose that accumulating
levels of physiological DNA damage perturb RNA splicing andthus impair the differentiation of specific progenitor sub-popula-
tions, possibly via de-regulation of epigenetic and DNA repair
factors. This is consistent with previous studies which have
demonstrated that genetic alterations in DNA repair genes can
result in BM failure syndromes and familial MDS by altering dif-
ferentiation of hematopoietic cells (Geiselhart et al., 2012;
Owen et al., 2008). Furthermore, it is tempting to speculate
that defective DNA repair in these progenitors may also fuel sec-
ondary events that predispose to AML transformation. This mayCancer Cell 27, 644–657, May 11, 2015 ª2015 Elsevier Inc. 653
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be of considerable relevance for the disease progression and
subsequent AML transformation that is frequently seen in MDS
patients and is consistent with the view that leukemic stem cells
often display a progenitor rather than a stem cell phenotype in
AML (Goardon et al., 2011).
Through pharmacologic and genetic perturbation of RNA
splicing, we provided evidence that aberrant RNA splicing alone
impairs CMP differentiation, supporting the view that aberrant
RNA splicing upon telomere dysfunction is one of the mecha-
nisms underlying the skewed myeloid differentiation (and MDS
phenotypes) seen in vivo. Indeed, reduced SRSF2 expression
in the Vav-cre/ SRSF2L/+ mouse model partially recapitulates
the MDS features observed in the telomere dysfunctional mice.
An unanticipated finding is that both SRSF2 haploinsufficiency
and SRSF2 mutation resulted in the aberrant splicing of genes
that are involved in telomeremaintenance, DNA repair, and chro-
matin remodeling—pathways extremely relevant to MDS patho-
genesis—which are also altered in the telomere dysfunctional
CMP as a consequence of DNA damage-induced downregula-
tion of splicing factor expression. Furthermore, our observation
that splicing de-regulation induces telomere dysfunction under-
scores a connection between RNA splicing and telomere
biology, which warrants further investigation.
Despite significant convergence of pathways with mutant
SRSF2 and SRSF2 haploinsufficiency, we also observed differ-
ences in the aberrantly spliced transcripts, suggesting that the
process of RNA splicing is executed differentially with SRSF2
mutation compared to its loss of function (e.g., different splice
site recognition), which may explain the weaker MDS phenotype
observed in Vav-cre/ SRSF2L/+ mice. This observation concurs
with what has been shown for the splicing gene PRPF8 (Kur-
tovic-Kozaric et al., 2014) and is consistent with many other
examples of cancer relevant genes, such as the TP53 tumor sup-
pressor gene, whereby TP53 deletion and TP53 mutation share
many commonalities in cancer pathogenesis, but are not iden-
tical in function (Lang et al., 2004).
In conclusion, our studies reveal an intimate relationship be-
tween telomeres and mRNA splicing in the control of cellular dif-
ferentiation of specific hematopoietic cell sub-populations, but
the molecular details are still to be clarified. We propose that
telomere dysfunction causes aberrant RNA splicing (by downre-
gulating splicing factors), which exacerbates telomere erosion
(by aberrantly splicing of telomere maintenance genes), impair-
ing progenitor cell differentiation, culminating in the eventual
progression to AML. Our results are consistent with the long-
standing clinical observations that poor prognosis in MDS corre-
lates strongly with short telomeres and elevated DNA damage
accumulation in myeloid progenitor cells and that therapy-
related MDS can result from cancer treatments utilizing alkylat-
ing agents or ionizing radiations. The improved understandingFigure 6. Aberrant RNA Splicing due to Altered SRSF2 Function Induc
(A) Significantly enriched pathways relative to the 1,357 aberrantly spliced genes
(B) Telomere-FISH and anti-gH2AX immunofluorescence in CMP sorted from 5-m
localization: yellow; and n = 5 Vav-cre and n = 7 Vav-cre/ SRSF2L/+); numbers of
and representative images (right panel) (the scale bar represents 10 mm).
(C) Mean value of telomere length in primary BM cells of 5-month-old mice of indic
data are expressed as percentage of the Vav-cre control).
(D) Significantly enriched pathways relative to the 1,355 aberrantly spliced genes
Tables S6 and S7.of DNA-damage induced perturbations in the splicing of specific
transcripts and linked pathways reported here should provide
highly specific risk biomarkers and therapeutic targets for the
prevention or treatment of this incurable disease.
EXPERIMENTAL PROCEDURES
Generation and Analysis of Mice
Mice were maintained in specific pathogen-free (SPF) conditions at MD
Anderson Cancer Center. All manipulations were performed with institu-
tional animal care and use committee (IACUC) approval. The heterozy-
gous (G0 TERTER/+) and late generation homozygous (G4/G5 TERTER/ER)
mice were generated based on standard breeding protocol of successive
generations of telomerase-deficient mice (Jaskelioff et al., 2011). All
studies were performed on adult (12–16 week old) G0 TERTER/+ and telo-
mere dysfunctional G4/G5 TERTER/ER mice, unless otherwise noted. OHT
time-release pellets (2.5 milligrams [mg]; Innovative Research of America)
were inserted subcutaneously to reach steady-state blood levels of 1
nanogram (ng) milliliter (ml)1 OHT. The conditional deletion of SRSF2
in the hematopoietic compartment was accomplished by crossing Vav-
cre mice (Jackson laboratories) with the srsf2L/L mice (Jackson labora-
tories) to generate heterozygous Vav-cre/ SRSF2L/+ mice. Animals were
autopsied, and the BM and spleen tissues were examined regardless
of their pathological status. Details are described in Supplemental Exper-
imental Procedures.
Human Primary Samples
Human MDS or CMML BM specimens were obtained from patients referred to
the Department of Leukemia at MD Anderson Cancer Center following proto-
col LAB01-473, which was approved by MD Anderson’s Institutional Review
Board. Written informed consent was obtained from donors. MDS BM cells
were collected from 57MDS and 15 CMML patients. Diagnosis was confirmed
by a dedicated hematopathologist and patients were classified as lower or
higher risk MDS according to the International Prognostic Scoring System
(IPSS). Isolation of CD34+ cells was performed using MicroBead Kit (Miltenyi),
following manufacturer’s instructions. An aliquot of purified CD34+ cells was
used to prepare cytospin slides; the remainder was subjected to centrifugation
at 300 3 g for 10 min and resuspended in TRIzol (Invitrogen) for RNA
extraction.
Flow Cytometry Analysis
Single-cell suspensions were prepared from spleen and BM (from femoral and
tibial bones). For fluorescence-activated cell sorter (FACS) sorting and anal-
ysis, we used described staining protocols and published stem and progenitor
cell definitions (Amrani et al., 2011; Flach et al., 2014). Details are described in
Supplemental Experimental Procedures.
Indirect Immunofluorescence Microscopy and Tif Assay
Sorted progenitor cells were resuspended in PBS, spotted on immunofluores-
cence slides, fixed, and immuno-stained with anti-phospho-gH2AX (1:200;
clone number JBW301, Millipore), 53BP1 (1:200, catalog number IHC00001,
Bethyl Laborathories), or phospho-ATR (1:50; catalog number 2853, Cell
Signaling). For Tif assay, cells were co-stained with phospho-H2AX and the
telomere specific PNA probe using the Telomere PNA FISH Kit/Cy3, according
to the manufacturer’s instructions. Details are described in Supplemental
Experimental Procedures.es Telomere Dysfunction
(p < 0.05) in the Vav-cre/ SRSF2L/+ mice.
onth-old mice of indicated genotypes (telomere: red; anti-gH2AX: green; co-
telomere dysfunction-induced foci per cell (left panel) (error bars denote SEM);
ated genotypes, as determined by flow-FISH analysis (error bars denote SEM;
(p < 0.01) in CMML patients with SRSF2 (P95) mutation. See also Figure S6 and
Cancer Cell 27, 644–657, May 11, 2015 ª2015 Elsevier Inc. 655
Treatments and Colony Forming Assay
MNCs (20 3 104/replicate) or sorted CMP (500 cells/replicate) were seeded
into cytokine supplemented methylcellulose medium or pre-treated with a
specific inhibitor of ATR, ATM, cisplatin, PLA-B, or NSC663284 prior to seed-
ing. Colonies were counted after 7–10 days. Erythroid cells were scored by
benzidine staining. Details are described in Supplemental Experimental
Procedures.
Microarray and Pathway Analysis
BM, CMP, and GMP cells were sorted from two paired pools of G0
TERTER/+ or G4/G5 TERTER/ER mice (5,000–20,000 cells per sample) and
RNA was extracted using TRIzol. Gene expression profiling was performed
with GeneChip Mouse Genome 430 2.0 Array (Affymetrix) and enriched
pathways were identified using GSEA (http://www.broadinstitute.org/
gsea/msigdb/annotate.jsp). Details are described in Supplemental Experi-
mental Procedures.
Single-Cell Gene Expression Profiling
Single CMP cells were sorted directly into 96-well plates before Fluidigm-
based real-time PCR analysis. Details are described in Supplemental Experi-
mental Procedures.
RNA-Seq and Analysis
Total RNA from sorted CMP isolated from three independent G0 TERTER/+ and
four G4/G5 TERTER/ER, three Vav-cre, and six Vav-cre /Srsf2L/+mice, as well as
CMML patient-derived CD34+ cells (n = 15) were isolated by TRIzol, before
RNA amplification and RNA-seq library construction. Transcriptomic
sequencing (RNA-seq) was performed on the Illumina HiSeq platform using
the standard paired-end protocol. Mapping of RNA-seq reads was performed
with Tophat2 and the National Center for Biotechnology Information (NCBI)
RefSeq gene model and HTSeq software were used to quantify the gene-level
expression, exon-specific expression, and intron retention levels. The differen-
tial analyses for gene/isoform expression and intron retention were analyzed
with DESeq2 (Anders and Huber, 2010), while exon usage was analyzed
with DEXSeq (Anders et al., 2012). Pathway enrichment analysis was per-
formed with Pathway Studio. Details are described in Supplemental Experi-
mental Procedures.
Western Blotting
Western blotting in small amount of cells was performed as previously
described (Nakada et al., 2010). Antibodies were anti-sfrs2 (clone number
1SC-4F11, Millipore), anti-sf3b2 (clone number 5D2, Sigma), anti-dnmt3a
(clone number H-295, Santa Cruz), anti-terf2ip (clone number D9H4, Cell
Signaling), and anti-vinculin (clone number hVIN-1, Sigma). Details are
described in Supplemental Experimental Procedures.
BM Transplantations
Donor derived peripheral blood reconstitution (i.e., chimerism) was assessed
after 2 or 4 months following transplantation by FACS analysis of nucleated
peripheral blood cells stained with anti-CD45.1 and anti-CD45.2-specific anti-
bodies. Blood chimerism for each recipient was calculated as the percentage
of all CD45+ cells that were CD45.2+. Details are described in Supplemental
Experimental Procedures.
Statistical Analysis
All the data were analyzed by a two-tailed Student’s t test (p < 0.05 is consid-
ered to be statistically significant). For all experiments with error bars, SEM
was calculated to indicate the variation within each experiment and data,
and values represent mean ± SEM or mean ± SD, as indicated in the figure
legends.
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